Colorectal Cancer Patient Survival Biomarker Study 2015-2017

A retrospective cohort study of 1,436 colorectal cancer patients who underwent surgical resection between 2015 and 2017. It analyzes the prognostic value of the Albumin/Neutrophil-to-Lymphocyte Ratio (ANLR) for progression-free and overall survival, with a median follow-up of 65 months.

Use Cases

• Train survival models using ANLR, progression-free survival (PFS), and overall survival (OS) data from 1,436 patient records.
• Assess the association between ANLR and sarcopenia risk using the reported odds ratio (OR = 0.593).
• Validate ANLR-based nomogram predictions for 1-, 3-, and 5-year survival rates against traditional TNM staging.
• Analyze the relationship between ANLR and postoperative complication risk (OR = 0.564).

Strengths

• Study includes 1,436 patient records from a single institution.
• Median follow-up duration of 65 months provides long-term outcome data.
• Reports specific hazard ratios (e.g., HR = 0.745 for PFS) and odds ratios from multivariate analyses.
• Nomogram models show high predictive accuracy with C-indices of 0.719 for PFS and 0.727 for OS.

Limitations

• Data is presented in a 93.6 KB PDF report; underlying tabular patient data is not directly accessible.
• Retrospective, single-institution study design may limit generalizability.
• Sample is limited to patients from a specific 2015-2017 surgical cohort.

Provenance

Source

Hailun Xie via figshare.

Collection Method

Retrospective cohort study of patients who underwent surgical resection at a single institution.

Time Range

Patient treatment from 2015 to 2017, with a median follow-up of 65 months.

Freshness

Data covers patients treated between 2015 and 2017, with study results published in 2026.

Geography

Single institution; specific location not stated.